Difference between revisions of "Drug index"
Jump to navigation
Jump to search
m (→L: added Lurbinectedin (Zepzelca)) Tag: visualeditor |
m (→N) |
||
| Line 518: | Line 518: | ||
*[[Nabilone (Cesamet)]] | *[[Nabilone (Cesamet)]] | ||
| + | *[[Naxitamab-gqgk (Danyelza)]] '''FDA approved 11/24/2020''' | ||
*[[Necitumumab (Portrazza)]] | *[[Necitumumab (Portrazza)]] | ||
*[[Nedaplatin (Aqupla)]] | *[[Nedaplatin (Aqupla)]] | ||
Revision as of 00:18, 26 November 2020
Guidelines
| back to top |
Other interesting and helpful links can be found by clicking the link.
Chemotherapy safety standards
- 2020: Dillmon et al. Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards PubMed
- 2019: Celano et al. Safe handling of hazardous drugs: ASCO standards PubMed
- 2016: Neuss et al. 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology
- 2010: Carrington et al. The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy PubMed
Dose adjustments
- 2012: Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline[1]
Antimicrobials
Growth factors
- 2015: Update of ASCO Clinical Practice Guideline recommendations for the use of WBC growth factors[2]
Alphabetically
A
| back to top |
- Abarelix (Plenaxis)
- Abciximab (ReoPro)
- Abemaciclib (Verzenio)
- Abexinostat (PCI-24781) in clinical trials
- Abiraterone (Zytiga)
- Acalabrutinib (Calquence)
- Acetaminophen (Tylenol)
- Aclarubicin (Aclacinomycin)
- Actinium Ac 225 lintuzumab (Actimab-A) in clinical trials
- Acyclovir (Zovirax)
- Adenovirus-interferon-γ (TG1042) in clinical trials
- Ado-trastuzumab emtansine (Kadcyla)
- Afatinib (Gilotrif)
- Afuresertib (GSK2110183) in clinical trials
- Aldesleukin (Proleukin)
- Alectinib (Alecensa)
- Alemtuzumab (Campath)
- Alendronate (Fosamax)
- Alisertib (MLN8237) in clinical trials
- Alitretinoin (Panretin)
- All-trans retinoic acid (ATRA)
- Allopurinol (Zyloprim)
- Alpelisib (Piqray) FDA approved 5/24/2019
- Alprazolam (Xanax)
- Altretamine (Hexalen)
- Alvocidib (Flavopiridol)
- Amatuximab (MORAb-009) in clinical trials
- AMG 330 in clinical trials
- Amifostine (Ethyol)
- Aminocaproic acid (Amicar)
- Aminoglutethimide (Cytadren)
- Aminopterin
- Amonafide (Quinamed) in clinical trials
- Amoxicillin
- Amrubicin (Calsed)
- Amsacrine (Amsidine)
- Anagrelide (Agrylin)
- Anastrozole (Arimidex)
- Ancestim (Stemgen)
- Anti-inhibitor coagulant complex (FEIBA NF)
- Antithrombin III (human and recombinant)
- Antithymocyte globulin, horse ATG (Atgam)
- Antithymocyte globulin, rabbit ATG (Grafalon)
- Antithymocyte globulin, rabbit ATG (Thymoglobulin)
- Apalutamide (Erleada)
- Apatinib (Aitan)
- Apixaban (Eliquis)
- Apocept (APG101) in clinical trials
- Aprepitant (Emend)
- Argatroban (Acova)
- Arsenic trioxide (Trisenox)
- Asciminib (ABL001) in clinical trials
- Ascorbic acid (Vitamin C)
- Asparaginase (Elspar) discontinued
- Asparaginase Erwinia chrysanthemi (Erwinaze)
- Aspirin
- Aspirin and dipyridamole (Aggrenox)
- Astuprotimut-R (GSK1572932A) in clinical trials
- Atezolizumab (Tecentriq)
- Atropine (Atropen)
- Atovaquone (Mepron)
- Avapritinib (Ayvakit) FDA approved 1/9/2020
- Avatrombopag (Doptelet)
- Avelumab (Bavencio)
- Axicabtagene ciloleucel (Yescarta)
- Axitinib (Inlyta)
- Azacitidine (Onureg) FDA approved 9/1/2020
- Azacitidine (Vidaza)
B
| back to top |
- Bacillus Calmette-Guérin (BCG)
- Barasertib (AZD1152) in clinical trials
- Bavituximab (PGN401) in clinical trials
- bb2121 in clinical trials
- Belagenpumatucel-L (Lucanix) in clinical trials
- Belantamab mafodotin (Blenrep) FDA approved 8/6/2020
- Belinostat (Beleodaq)
- Belotecan (Camptobell)
- Bendamustine
- Benralizumab (Fasenra)
- Betrixaban (Bevyxxa)
- Bevacizumab (Avastin)
- Bevacizumab-awwb (Mvasi)
- Bevacizumab-bvzr (Zirabev)
- Bexarotene (Targretin)
- Bicalutamide (Casodex)
- Binimetinib (MEK162) in clinical trials
- Bivalirudin (Angiomax)
- BHQ880 in clinical trials
- BL22 immunotoxin (CAT-3888) in clinical trials
- Bleomycin (Blenoxane)
- Blinatumomab (Blincyto)
- Bortezomib (Velcade)
- Bosutinib (Bosulif)
- Brentuximab vedotin (Adcetris)
- Brexucabtagene autoleucel (Tecartus) FDA approved 7/24/2020
- Brigatinib (Alunbrig)
- Buparlisib (BKM120) in clinical trials
- Buserelin (Suprefact)
- Busulfan (Myleran)
C
| back to top |
- Cabazitaxel (Jevtana)
- Cabozantinib (Cabometyx)
- Cabozantinib (Cometriq)
- Calaspargase (Asparlas)
- Calcium phosphate rinse (Caphosol)
- Cangrelor (Kengreal)
- Capecitabine (Xeloda)
- Capivasertib (AZD5363) in clinical trials
- Caplacizumab (Cablivi) FDA approved 1/6/2019
- Capmatinib (Tabrecta) FDA approved 5/6/2020
- Carboplatin (Paraplatin)
- Carfilzomib (Kyprolis)
- Carmustine (BCNU)
- Carmustine wafer, polifeprosan 20 (Gliadel)
- Caspofungin (Cancidas)
- Catumaxomab (Removab) in US clinical trials
- Cediranib (Recentin) in clinical trials
- Cemiplimab (Libtayo)
- Ceritinib (Zykadia)
- Cetirizine (Zyrtec)
- Cetuximab (Erbitux)
- Chidamide (Epidaza)
- Chlorambucil (Leukeran)
- Chlorozotocin (DCNU)
- Chlorpheniramine (Chlor-Trimeton)
- Cilostazol (Pletal)
- Cimetidine (Tagamet)
- Ciprofloxacin (Cipro)
- Cisplatin (Platinol)
- Cixutumumab (IMC-A12) in clinical trials
- Cladribine (Leustatin)
- Clarithromycin (Biaxin)
- Clemastine (Tavist)
- Clodronate (Bonefos)
- Clofarabine (Clolar)
- Clopidogrel (Plavix)
- Cobimetinib (Cotellic)
- Coltuximab ravtansine (CoR, SAR3419) in clinical trials
- Copanlisib (Aliqopa)
- Cortisone
- Crenolanib (CP-868,596) in clinical trials
- Crizanlizumab (Adakveo) FDA approved 11/15/2019
- Crizotinib (Xalkori)
- Custirsen (OGX-011) in clinical trials
- Cyanocobalamin (Vitamin B12)
- Cyclophosphamide (Cytoxan)
- Cyclosporine modified (Neoral)
- Cyclosporine non-modified (Sandimmune)
- Cyproterone acetate (Androcur)
- Cytarabine (Ara-C)
- Cytarabine and daunorubicin liposomal (Vyxeos)
- Cytarabine liposomal (DepoCyt)
- Cytomegalovirus Immune Globulin (Cytogam)
D
| back to top |
- Dabigatran (Pradaxa)
- Dabrafenib (Tafinlar)
- Dacarbazine (DTIC)
- Dacomitinib (Vizimpro)
- Dactinomycin (Cosmegen)
- Dalteparin (Fragmin)
- Danazol (Danocrine)
- Dapsone (Aczone)
- Daratumumab (Darzalex)
- Daratumumab and hyaluronidase (Darzalex Faspro) FDA approved 5/1/2020
- Darbepoetin alfa (Aranesp)
- Darolutamide (Nubeqa) FDA approved 7/30/2019
- Dasatinib (Sprycel)
- Daunorubicin (Cerubidine)
- Daunorubicin liposomal (DaunoXome)
- Decitabine (Dacogen)
- Decitabine and cedazuridine (Inqovi) FDA approved 7/7/2020
- Deferasirox (Exjade)
- Deferasirox (Jadenu)
- Deferiprone (Ferriprox)
- Deferoxamine (Desferal)
- Defibrotide (Defitelio)
- Degarelix (Firmagon)
- Denileukin diftitox (Ontak)
- Denintuzumab mafodotin (SGN-CD19A) in clinical trials
- Denosumab (Xgeva)
- Desmopressin (DDAVP)
- Dexamethasone (Decadron)
- Dexchlorpheniramine (Polaramine)
- Dexrazoxane (Zinecard)
- Diethylstilbestrol (DES)
- Dinaciclib (SCH 727965) in clinical trials
- Dinutuximab (Unituxin)
- Diphenhydramine (Benadryl)
- Dipyridamole (Persantine)
- Discodermolide (XAA296) in clinical trials
- DMUC5754A in clinical trials
- Docetaxel (Taxotere)
- Docusate (Colace)
- Dolasetron (Anzemet)
- Domperidone (Motilium)
- Dovitinib (TKI-258) in clinical trials
- Doxifluridine (Didox)
- Doxorubicin (Adriamycin)
- Pegylated liposomal doxorubicin (Doxil)
- Doxycycline
- Dronabinol (Marinol)
- Durvalumab (Imfinzi)
- Dutasteride (Avodart)
- Duvelisib (Copiktra)
E
| back to top |
- Eculizumab (Soliris)
- Edoxaban (Savaysa)
- Edrecolomab (Panorex)
- Elotuzumab (Empliciti)
- Eltrombopag (Promacta)
- Emapalumab (Gamifant)
- Emicizumab-kxwh (Hemlibra)
- Emepepimut-S (Stimuvax) in clinical trials
- Enasidenib (Idhifa)
- Encorafenib (LGX818) in clinical trials
- Enfortumab vedotin (Padcev) FDA approved 12/18/2019
- Enoxaparin (Lovenox)
- Ensartinib (X-396) in clinical trials
- Entinostat (SNDX-275) in clinical trials
- Entospletinib (GS-9973) in clinical trials
- Entrectinib (Rozlytrek) FDA approved 8/15/2019
- Enzalutamide (Xtandi)
- Epirubicin (Ellence)
- Epoetin alfa (Procrit)
- Epoetin alfa-epbx (Retacrit)
- Epratuzumab (LymphoCide) in clinical trials
- Eptifibatide (Integrilin)
- Erdafitinib (Balversa) FDA approved 4/12/2019
- Eribulin (Halaven)
- Erlotinib (Tarceva)
- Estradiol
- Estramustine (Emcyt)
- Etirinotecan pegol (NKTR-102) in clinical trials
- Etoposide (Vepesid)
- Everolimus (Afinitor)
- Exemestane (Aromasin)
F
| back to top |
- Factor VIIa, recombinant (NovoSeven RT)
- Factor VIII, human
- Factor VIII, recombinant
- Factor IX, human
- Factor IX, recombinant
- Factor IX, recombinant, Fc fusion protein (Alprolix)
- Factor X, human (Coagadex)
- Factor Xa, recombinant, inactivated-zhzo (Andexxa)
- Factor XIII concentrate, human (Corifact)
- Famciclovir (Famvir)
- Famotidine (Pepcid)
- Fam-trastuzumab deruxtecan (Enhertu) FDA approved 12/20/2019
- Fedratinib (Inrebic) FDA approved 8/16/2019
- Ferric carboxymaltose (Injectafer)
- Ferric gluconate (Ferrlecit)
- Ferrous sulfate (Feosol)
- Ferumoxytol (Feraheme)
- Fibrinogen concentrate, human (RiaSTAP)
- Filanesib (ARRY-520) in clinical trials
- Filgrastim (Neupogen)
- Filgrastim-aafi (Nivestym)
- Filgrastim-sndz (Zarxio)
- Finasteride (Proscar)
- Fluorouracil (5-FU)
- Floxuridine (FUDR)
- Fluconazole (Diflucan)
- Fludarabine (Fludara)
- Fluoxymesterone (Halotestin)
- Flutamide (Eulexin)
- Folic acid (Folate)
- Folinic acid (Leucovorin)
- Fondaparinux (Arixtra)
- Formestane (Lentaron)
- Forodesine (Fodosine) in clinical trials
- Fosaprepitant (Emend for Injection)
- Fostamatinib (Tavalisse)
- Fotemustine (Muphoran) in clinical trials
- Fruquintinib (HMPL-013) in clinical trials
- Fulvestrant (Faslodex)
- Furosemide (Lasix)
- Futibatinib (TAS-120) in clinical trials
G
| back to top |
- Galeterone (TOK-001) in clinical trials
- Galunisertib (LY2157299) in clinical trials
- Ganetespib (STA-9090) in clinical trials
- Ganitumab (AMG 479) in clinical trials
- Gefitinib (Iressa)
- Gemcitabine (Gemzar)
- Gemcitabine elaidate (CP-4126, CO-101) in clinical trials
- Gemtuzumab ozogamicin (Mylotarg) FDA approved 9/1/17
- Gilteritinib (Xospata)
- Glasdegib (Daurismo)
- Glembatumumab vedotin (CDX-011)] in clinical trials
- Glucarpidase (Voraxaze)
- Goserelin (Zoladex)
- Granisetron (Kytril)
- Granisetron (Sancuso)
- Granisetron (Sustol)
- Guadecitabine (SGI-110) in clinical trials
H
| back to top |
- Haloperidol (Haldol)
- Hematopoetic progenitor cells, cord blood (Hemacord)
- Heptaplatin (Sunpla)
- HER2 peptide vaccine (AE37) in clinical trials
- Histrelin (Vantas)
- Hu5F9-G4 in clinical trials
- Hydrocortisone (Cortef)
- Hydroxyurea (Hydrea)
I
| back to top |
- Ibandronate (Boniva)
- Ibritumomab tiuxetan (Zevalin)
- Ibrutinib (Imbruvica)
- Icotinib (Conmana)
- Idarubicin (Idamycin)
- Idarucizumab (Praxbind)
- Idasanutlin (RG7388) in clinical trials
- Idelalisib (Zydelig)
- Ifosfamide (Ifex)
- IMA901 in clinical trials
- Imatinib (Gleevec)
- Imetelstat (GRN163L) in clinical trials
- Indatuximab ravtansine (BT062) in clinical trials
- Indomethacin (Indocin)
- Infigratinib (BGJ398) in clinical trials
- Inotuzumab ozogamicin (Besponsa)
- Interferon alfa-2a (Roferon-A)
- Interferon alfa-2b (Intron-A)
- Interferon gamma-1b (Actimmune)
- Iobenguane I 131 (Azedra)
- Iodine-131
- Ipatasertib (GDC-0068) in clinical trials
- IPH 2101 in clinical trials
- Ipilimumab (Yervoy)
- Irinotecan (Camptosar)
- Irinotecan liposome (Onivyde)
- Iron dextran (INFeD)
- Iron sucrose (Venofer)
- Isatuximab (Sarclisa) FDA approved 3/2/2020
- Isotretinoin (Accutane)
- Itraconazole (Sporanox)
- Ivosidenib (Tibsovo)
- Ixabepilone (Ixempra)
- Ixazomib (Ninlaro)
J
- JCAR015 in clinical trials
K
L
| back to top |
- Lactulose
- Lamivudine (Epivir)
- Lanreotide (Somatuline)
- Lansoprazole (Prevacid)
- Lapatinib (Tykerb)
- Lapuleucel-T (DN24-02) in clinical trials
- Larotrectinib (Vitrakvi)
- Lasofoxifene (Fablyn) not FDA approved
- Lenalidomide (Revlimid)
- Lenograstim (Granocyte)
- Lenvatinib (Lenvima)
- Lepirudin (Refludan) discontinued
- Lestaurtinib (CEP-701) in clinical trials
- Letermovir (Prevymis)
- Letrozole (Femara)
- Leuprolide (Lupron)
- Levamisole (Ergamisol)
- Levofloxacin (Levaquin)
- Levoleucovorin (Fusilev)
- L-glutamine (Endari)
- Linifanib (ABT-869) in clinical trials
- Linsitinib (OSI-906) in clinical trials
- Lipefilgrastim (XM22) in clinical trials
- Lisocabtagene maraleucel (Liso-cel) in clinical trials
- Lobaplatin (D-19466)
- Lomustine (CCNU)
- Loperamide (Imodium)
- Lorazepam (Ativan)
- Lorlatinib (Lorbrena)
- Lorvotuzumab mertansine (BB-10901) in clinical trials
- Lurbinectedin (Zepzelca) FDA approved 6/15/2020
- Luspatercept (Reblozyl) FDA approved 11/8/2019
- Lusutrombopag (Mulpleta)
- Lutetium Lu 177 dotatate (Lutathera)
- LY3023414 in clinical trials
M
| back to top |
- Mannitol
- Mapatumumab (HGS-ETR1) in clinical trials
- Masitinib (AB1010) in clinical trials
- Mechlorethamine (Mustargen)
- Medroxyprogesterone (MPA)
- Megestrol (Megace)
- Melphalan (Alkeran)
- Meperidine (Demerol)
- Mepolizumab (Nucala)
- Mercaptopurine (6-MP)
- Mesna (Mesnex)
- Methotrexate (MTX)
- Methoxsalen (Uvadex)
- Methylprednisolone (Solumedrol)
- Methyltesterone (Android)
- Metoclopramide (Reglan)
- Midostaurin (Rydapt)
- Mifamurtide (Mepact)
- Milataxel (TL139) in clinical trials
- Mirvetuximab soravtansine (IMGN853) in clinical trials
- Mitomycin (Jelmyto) FDA approved on 4/15/2020
- Mitomycin (Mutamycin)
- Mitotane (Lysodren)
- Mitoxantrone (Novantrone)
- MK2206 in clinical trials
- Mocetinostat (MGCD0103) in clinical trials
- Mogamulizumab (Poteligeo)
- Momelotinib (CYT387) in clinical trials
- MOR208 in clinical trials
- Motesanib (AMG 706) in clinical trials
- Moxetumomab pasudotox (Lumoxiti)
- Mycophenolate mofetil (CellCept)
N
| back to top |
- Nabilone (Cesamet)
- Naxitamab-gqgk (Danyelza) FDA approved 11/24/2020
- Necitumumab (Portrazza)
- Nedaplatin (Aqupla)
- Nelarabine (Arranon)
- NEOD001
- Neratinib (Nerlynx)
- Netupitant and palonosetron (Akynzeo)
- Nilotinib (Tasigna)
- Nilutamide (Nilandron)
- Nimustine (ACNU)
- Nintedanib (Vargatef)
- Niraparib (Zejula)
- Nivolumab (Opdivo)
- Nolatrexed (Thymitaq)
- Non-pegylated liposomal doxorubicin (Myocet)
- Norethandrolone (Nilevar)
- NovoTTF-100A system (Optune)
O
| back to top |
- Obinutuzumab (Gazyva)
- Octreotide (Sandostatin)
- Octreotide LAR (Sandostatin LAR)
- Ofatumumab (Arzerra)
- Olanzapine (Zyprexa)
- Olaparib (Lynparza)
- Olaptesed pegol (NOX-A12) in clinical trials
- Olaratumab (Lartruvo) discontinued
- Omacetaxine (Synribo)
- Omeprazole (Prilosec)
- Onartuzumab (MetMAb) in clinical trials
- Ondansetron (Zofran)
- Oprelvekin (Neumega)
- Oprozomib (ONX 0912) in clinical trials
- Orteronel (TAK-700) in clinical trials
- Osimertinib (Tagrisso)
- Osocimab (BAY 1213790) in clinical trials
- Otlertuzumab (TRU-016) in clinical trials
- Oxaliplatin (Eloxatin)
P
| back to top |
- Paclitaxel (Taxol)
- Paclitaxel, nanoparticle albumin-bound (Abraxane)
- Paclitaxel, polymeric micelle-bound (Genexol-PM)
- Pacritinib (SB1518) in clinical trials
- Palbociclib (Ibrance)
- Palifermin (Kepivance)
- Palonosetron (Aloxi)
- Pamidronate (Aredia)
- Panitumumab (Vectibix)
- Panobinostat (Farydak)
- Pantoprazole (Protonix)
- Pazopanib (Votrient)
- Pegaspargase (Oncaspar)
- Pegfilgrastim (Neulasta)
- Pegfilgrastim-bmez (Ziextenzo)
- Pegfilgrastim-cbqv (Udenyca)
- Pegfilgrastim-jmdb (Fulphila)
- Peginterferon alfa-2a (Pegasys)
- Peginterferon alfa-2b (Sylatron)
- Pembrolizumab (Keytruda)
- Pemetrexed (Alimta)
- Pemigatinib (Pemazyre) FDA approved 4/17/2020
- Penicillin V
- Pentamidine (Nebupent)
- Pentostatin (Nipent)
- Pentraxin 2 (PRM-151) in clinical trials
- Perifosine (KRX-0401) in clinical trials
- Pertuzumab (Perjeta)
- Pexidartinib (Turalio) FDA approved 8/2/2019
- Phenytoin (Dilantin)
- Phosphomannopentaose sulfate (PI-88) in clinical trials
- Phytonadione (Vitamin K)
- Pictilisib (GDC-0941) in clinical trials
- Pidilizumab (CT-011) in clinical trials
- Pinatuzumab vedotin (DCDT2980S) in clinical trials
- Pirarubicin (THP)
- Pixantrone (Pixuvri)
- Plerixafor (Mozobil)
- Plicamycin (Mithracin)
- Plinabulin (NPI-2358) in clinical trials
- Polatuzumab vedotin (Polivy) FDA approved 6/10/2019
- Pomalidomide (Pomalyst)
- Ponatinib (Iclusig)
- Porfimer (Photofrin)
- Pracinostat (SB939) in clinical trials
- Pralatrexate (Folotyn)
- Pralsetinib (Gavreto) FDA approved 9/4/2020
- Prasugrel (Effient)
- Pravastatin (Pravachol)
- Prednisone (Sterapred)
- Prednisolone (Millipred)
- Procarbazine (Matulane)
- Prochlorperazine (Compazine)
- Promethazine (Phenergan)
- Protamine sulfate
- Prothrombin Complex Concentrate, human
Q
- Quinine (Qualaquin)
- Quisinostat (JNJ-26481585) in clinical trials
- Quizartinib (AC220) in clinical trials
R
| back to top |
- Rabeprazole (Aciphex)
- Radium Ra 223 (Xofigo)
- Radotinib (Supect)
- Raloxifene (Evista)
- Raltitrexed (Tomudex)
- Ramosetron (Iribo)
- Ramucirumab (Cyramza)
- Ranimustine (Cymerin)
- Ranitidine (Zantac)
- Rasburicase (Elitek)
- Ravulizumab (Ultomiris)
- Realgar-Indigo naturalis formulation
- Refametinib (BAY 869766) in clinical trials
- Regorafenib (Stivarga)
- Relugolix (Relumina)
- Reovirus (Reolysin) in clinical trials
- Retaspimycin (IPI-504) in clinical trials
- Rho(D) immune globulin (RhoGAM)
- Ribociclib (Kisqali)
- Ricolinostat (ACY-1215, Rocilinostat) in clinical trials
- Ridaforolimus (AP23573) in clinical trials
- Rilotumumab (AMG 102) in clinical trials
- Ripretinib (Qinlock) FDA approved 5/15/2020
- Risedronate (Actonel)
- Rituximab (Rituxan)
- Rituximab-abbs (Truxima)
- Rituximab-pvvr (Ruxience) FDA approved 7/2019
- Rituximab and hyaluronidase human (Rituximab Hycela)
- Rivaroxaban (Xarelto)
- Rociletinib (CO-1686) in clinical trials
- Rolapitant (Varubi)
- Romidepsin (Istodax)
- Romiplostim (Nplate)
- Ropeginterferon alfa-2b (AOP2014) in clinical trials
- Rucaparib (Rubraca)
- Ruxolitinib (Jakafi)
S
| back to top |
- Sacituzumab govitecan (Trodelvy) FDA approved 4/22/2020
- Samarium-153 (Quadramet)
- Sapacitabine (CS-682) in clinical trials
- Sapanisertib (MLN0128) in clinical trials
- Sargramostim (Leukine)
- Scopolamine (Scopoderm)
- Seliciclib (CYC202) in clinical trials
- Selinexor (Xpovio) FDA approved 7/3/2019
- Selpercatinib (Retevmo) FDA approved 5/8/2020
- Selumetinib (Koselugo) FDA approved 4/10/2020
- Semuloparin (AVE5026) in clinical trials
- Semustine (MeCCNU)
- Sennosides (Senna)
- Siltuximab (Sylvant)
- Sipuleucel-T (Provenge)
- Sirolimus (Rapamune)
- Sonidegib (Odomzo)
- Sorafenib (Nexavar)
- Spebrutinib (CC-292) in clinical trials
- Stilbamidine
- Streptozocin (Zanosar)
- Strontium-89 (Metastron)
- Sunitinib (Sutent)
- Surufatinib (HMPL-012) in clinical trials
- Sutimlimab (BIVV009) in clinical trials
T
| back to top |
- Tabalumab (LY2127399) in clinical trials
- Tacrolimus (Prograf)
- Tafasitamab (Monjuvi) FDA approved 7/31/2020
- Tagraxofusp (Elzonris)
- Talazoparib (Talzenna)
- Talimogene laherparepvec (Imlygic)
- Tamibarotene (Amnoid) in clinical trials
- Tamoxifen (Nolvadex)
- Tazemetostat (Tazverik) FDA approved 1/23/2020
- Tbo-filgrastim (Granix)
- Tegafur and uracil (UFT)
- Tegafur, gimeracil, oteracil (Teysuno, S-1)
- Telotristat (Xermelo)
- Temozolomide (Temodar)
- Temsirolimus (Torisel)
- Teniposide (Vumon)
- Tepotinib (EMD-1214063) in clinical trials
- Tesetaxel (DJ-927) in clinical trials
- Tesevatinib (XL647) in clinical trials
- Testolactone (Teslac) discontinued
- Thalidomide (Thalomid)
- Thioguanine (Tabloid)
- Thiotepa (Tepadina)
- Thiotepa (Thioplex)
- Ticagrelor (Brilinta)
- Ticlodipine (Ticlid)
- Tigatuzumab (CS-1008) in clinical trials
- Tinzaparin (Innohep)
- Tipifarnib (Zarnestra) in clinical trials
- Tirabrutinib (GS-4059) in clinical trials
- Tirofiban (Aggrastat)
- Tisagenlecleucel (Kymriah) FDA approved 8/30/17
- Tivantinib (ARQ 197) in clinical trials
- Tivozanib (AV-951) in clinical trials
- Tocilizumab (Actemra)
- Tofacitinib (Xeljanz)
- Topotecan (Hycamtin)
- Toremifene (Fareston)
- Tosedostat (CHR-2797) in clinical trials
- Tositumomab & I-131 (Bexxar)
- Trabectedin (Yondelis)
- Trametinib (Mekinist)
- Tranexamic acid (Cyklokapron)
- Trastuzumab (Herceptin)
- Trastuzumab-anns (Kanjinti) FDA approved 6/2019
- Trastuzumab-dkst (Ogivri)
- Trastuzumab-dttb (Ontruzant) FDA approved 1/2019
- Trastuzumab-pkrb (Herzuma)
- Trastuzumab-qyyp (Trazimera) FDA approved 3/2019
- Trastuzumab and hyaluronidase (Herceptin Hylecta) FDA approved 2/28/2019
- Trebananib (AMG 386) in clinical trials
- Tremelimumab (ticilimumab) in clinical trials
- Treosulfan (Ovastat)
- Trifluridine and tipiracil (Lonsurf)
- Trilostane (Vetoryl)
- Trimethoprim-Sulfamethoxazole (Bactrim DS)
- Trimetrexate (Neutrexin)
- Triptorelin (Trelstar LA)
- Tropisetron (Navoban)
- Tucatinib (Tukysa) FDA approved 4/17/2020
U
- Ublituximab (TG-1101) in clinical trials
- Umbralisib (TGR-1202) in clinical trials
- Unfractionated heparin (UFH)
- Uracil mustard
- Urethane
- Uridine triacetate (Vistogard)
V
| back to top |
- Vadastuximab talirine (SGN-CD33A) in clinical trials
- Valacyclovir (Valtrex)
- Valganciclovir (Valcyte)
- Valproate (Depakote)
- Valrubicin (Valstar)
- Vandetanib (Caprelsa)
- Varlilumab (CDX-1127) in clinical trials
- Veliparib (ABT-888) in clinical trials
- Veltuzumab (hA20) in clinical trials
- Vemurafenib (Zelboraf)
- Venetoclax (Venclexta)
- Vinblastine (Velban)
- Vincristine (Oncovin)
- Vincristine liposomal (Marqibo)
- Vindesine (Eldisine)
- Vinflunine (Javlor)
- Vinorelbine (Navelbine)
- Vismodegib (Erivedge)
- Volasertib (BI 6727) in clinical trials
- von Willebrand factor and factor VIII complex, human
- von Willebrand factor, recombinant
- Vorapaxar (Zontivity)
- Voriconazole (Vfend)
- Vorinostat (Zolinza)
- Vosaroxin (SNS 595) in clinical trials
- Voxelotor (Oxbryta) FDA approved 11/25/2019
- Voxtalisib (XL765) in clinical trials
W
| back to top |
Z
- Zanubrutinib (Brukinsa) FDA approved 11/14/2019
- Ziv-aflibercept (Zaltrap)
- Zoledronic acid (Zometa)
By Category
Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is still in process so not all of these links are active).
Drugs in a REMS program
Cytotoxic Chemotherapy
| back to top |
- Alkylating agents
- Anthracyclines
- Antimetabolites
- DNA synthesis inhibitors
- Microtubule inhibitors
- Nitrogen mustards
- Nitrosureas
- Platinum agents
- Proteasome inhibitors
- Taxanes
- Topoisomerase inhibitors
- Vinca alkaloids
Kinase inhibitors
| back to top |
- AKT1 inhibitors
- ALK inhibitors
- Aurora kinase inhibitors
- AXL inhibitors
- Bcr-Abl inhibitors
- BRAF inhibitors
- BTK inhibitors
- CDK inhibitors
- EGFR inhibitors
- ERBB2 inhibitors
- ERBB4 inhibitors
- FGFR inhibitors
- FLT3 inhibitors
- IGFR inhibitors
- JAK inhibitors
- KIT inhibitors
- MEK inhibitors
- MET inhibitors
- mTOR inhibitors
- PDGFR inhibitors
- PI3K inhibitors
- PLK1 inhibitors
- RET inhibitors
- ROS1 inhibitors
- SRC inhibitors
- SYK inhibitors
- TEK inhibitors
- TRK inhibitors
- VEGF inhibitors
Endocrine therapy
| back to top |
- Antiandrogens
- Steroid synthesis inhibitors
- Androgen receptor inhibitors
- 5 alpha-reductase inhibitors
- GnRH agonists
- GnRH antagonists
- Aromatase inhibitors
- Selective estrogen receptor modulators
- Steroids
- Somatostatin analogs
Investigational and Discontinued
Biologics
| back to top |
- Antibody medications
- Antibody-drug conjugates
- Anti-HER2 medications
- IL-6 inhibitors
- Enzymes
- Immunotherapy
- Immunomodulatory drugs (IMiDs)
Supportive Medications
| back to top |
- Antibacterials
- Antidiarrheals
- Antifungals
- Antihistamines
- Antivirals
- Bisphosphonates
- Chemotherapy protective agents
- Emesis prevention
- PCP prophylaxis
- RANK ligand inhibitors
- Steroids
Radioactive agents
Benign Hematology Medications
| back to top |
Hematopoietic Growth Factors
| back to top |
Miscellaneous
| back to top |
- Drugs in a REMS program
- HDAC inhibitors
- Hypomethylating agents
- Retinoids
- WHO Essential Cancer Medicines
Medications by Condition
| back to top |
- Acute lymphocytic leukemia medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Anal cancer medications
- Anaplastic large cell lymphoma medications
- Basal cell and squamous cell skin cancer medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- Cancer of unknown primary medications
- Castleman’s disease medications
- Central nervous system (CNS) cancer medications
- Central nervous system (CNS) lymphoma medications
- Cervical cancer medications
- Chronic lymphocytic leukemia (CLL/SLL) medications
- Chronic myelogenous leukemia medications
- Chronic myelomonocytic leukemia medications
- Colon cancer medications
- Cutaneous T-cell lymphoma medications
- Diffuse large B-cell lymphoma medications
- Endometrial cancer medications
- Esophageal cancer medications
- Essential thrombocythemia medications
- Extranodal NK/T-cell lymphoma, nasal type lymphoma medications
- Follicular lymphoma medications
- Gastric cancer medications
- Hairy cell leukemia medications
- Head and neck cancer medications
- Hepatobiliary cancer medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Immune thrombocytopenic purpura (ITP) medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Melanoma medications
- Mesothelioma medications
- Multiple myeloma medications
- Myelodysplastic syndrome medications
- Myelofibrosis medications
- NK/T-cell lymphoma medications
- Non-small cell lung cancer medications
- Neuroendocrine tumor medications
- Ovarian cancer medications
- Pancreatic cancer medications
- Paroxysmal nocturnal hemoglobinuria (PNH) medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Plasma cell leukemia medications
- Polycythemia vera medications
- Primary mediastinal B-cell lymphoma medications
- Prostate cancer medications
- Rectal cancer medications
- Renal cell carcinoma medications
- Sarcoma medications
- Sickle cell anemia medications
- Small cell lung cancer medications
- T-cell lymphoma medications
- Testicular cancer medications
- Thymoma medications
- Thyroid cancer medications
- Transformed lymphoma medications
- Transplant medications
- Waldenström macroglobulinemia medications
Medications by Route of Administration
| back to top |
- Intraarterial (IA) medications
- Intracavitary medications
- Intramuscular (IM) medications
- Intrathecal (IT) medications
- Intravenous (IV) medications
- Intravesicular medications
- Oral (PO) medications
- Subcutaneous (SC) medications
Medications by Year of Approval
| back to top |
- FDA approved in 1939
- FDA approved in 1941
- FDA approved in 1946
- FDA approved in 1949
- FDA approved in 1951
- FDA approved in 1952
- FDA approved in 1953
- FDA approved in 1954
- FDA approved in 1955
- FDA approved in 1956
- FDA approved in 1957
- FDA approved in 1958
- FDA approved in 1959
- FDA approved in 1962
- FDA approved in 1963
- FDA approved in 1964
- FDA approved in 1965
- FDA approved in 1966
- FDA approved in 1967
- FDA approved in 1968
- FDA approved in 1969
- FDA approved in 1970
- FDA approved in 1971
- FDA approved in 1973
- FDA approved in 1974
- FDA approved in 1975
- FDA approved in 1976
- FDA approved in 1977
- FDA approved in 1978
- FDA approved in 1979
- FDA approved in 1980
- FDA approved in 1981
- FDA approved in 1982
- FDA approved in 1983
- FDA approved in 1984
- FDA approved in 1985
- FDA approved in 1986
- FDA approved in 1987
- FDA approved in 1988
- FDA approved in 1989
- FDA approved in 1990
- FDA approved in 1991
- FDA approved in 1992
- FDA approved in 1993
- FDA approved in 1994
- FDA approved in 1995
- FDA approved in 1996
- FDA approved in 1997
- FDA approved in 1998
- FDA approved in 1999
- FDA approved in 2000
- FDA approved in 2001
- FDA approved in 2002
- FDA approved in 2003
- FDA approved in 2004
- FDA approved in 2005
- FDA approved in 2006
- FDA approved in 2007
- FDA approved in 2008
- FDA approved in 2009
- FDA approved in 2010
- FDA approved in 2011
- FDA approved in 2012
- FDA approved in 2013
- FDA approved in 2014
- FDA approved in 2015
- FDA approved in 2016
- FDA approved in 2017
- FDA approved in 2018
- FDA approved in 2019
Interesting and Helpful Links
| back to top |
- Antidepressants and other psychiatric medications in cancer care
- Antiemetic support
- 2015 Update of ASCO Clinical Practice Guideline Recommendations for the Use of WBC Growth Factors[3]
- Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline (2013)
- Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline[4]
- 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology
- Chemotherapy Administration Sequence[5] - with chemotherapy sequencing chart
- The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. PubMed
- CredibleMeds.org - lists of QT-prolonging drugs; requires free registration to see full list
- FDA drug shortages list
- ASHP drug shortages list - also includes information about discontinued drugs
- DailyMed - a comprehensive NLM portal to all FDA-approved drugs
- Drugs@FDA - the main portal into the FDA drug database
- The NCI Drug Dictionary - an extensive resource with most antineoplastics (approved and in clinical trials) listed
- In the Pipeline - a blog from a veteran of the pharmaceutical industry, Derek Lowe. General but much is cancer-relevant. The old home of this blog is no longer active.
- Steroid conversions
- Vesicant & irritant chemotherapy
- Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers
- CPIC Guidelines The Clinical Pharmacogenetics Implementation Consortium provides guidelines for a small set of drugs with pharmacogenetically-guided dosing implications, some of which are oncologics
References
- ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
- ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13.
- ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13.
- ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
- ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article